Trial Profile
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 15 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Jul 2022.
- 15 Apr 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Jul 2022.